InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,295.20
(
-0.01%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
73.96
(
0.09%
)
Bitcoin
63,519.05
(
-0.16%
)
Post# of 253175
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 224678

Tuesday, 04/16/2019 12:44:25 PM

Tuesday, April 16, 2019 12:44:25 PM

Post# of 253175
ENTA/ASMB—Under no pressure from the investment community to rush its HBV program (thanks to the ample royalty income from HCV and its further advanced clinical programs in NASH and RSV), ENTA has spent several years selecting its lead HBV candidate, which is the polar opposite of the approach taken by ASBM. In short, I’m pretty confident that ENTA’s HBV CpAM compound will be a good one.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up